Applied immunohistochemistry & molecular morphology · 2014 · 24 citations · 27 references
MedicineCancer BiologyOncologyBreast OncologyEndocrine OncologyMolecular OncologyBreast PathologyCancer BiomarkersHer2-positive Breast CancerImmunohistochemistryMammary TumorsTumor MarkersBreast Cancer HistopathologyEstrogen Receptor StatusHer2 ExpressionHormone Receptor - Positive Breast CancerImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical Staining
There are a few studies that have evaluated a panel of stains on a single large data set of breast cancers, which is required for direct comparison between antibodies. The immunohistochemical panel in this study was chosen to include breast-specific markers and markers that are expressed in tumors resembling breast cancer. The individual marker positivity in decreasing order was 95% (177/186) for GATA-3, 92% (172/186) for cytokeratin (CK)7, 80% (151/189) for AR, 80% for estrogen receptor (158/198), 69% for progesterone receptor (137/198), 55% (105/190) for NY-BR-1, 52% (99/189) for mammaglobin, 31% (59/191) for vimentin, 26% (51/195) for GCDFP-15, 0.5% (1/186) for CK20, and 0% (0/188) for PAX-8. When tumors were categorized based on estrogen receptor and HER2 status; a total of 45 profiles were identified. In addition, some tumors showed an unconventional profile-although the majority of breast carcinomas were CK7-positive/CK20-negative, a CK7-negative/CK20-negative profile was seen in ∼8% of the cases. Such a profile can create confusion in investigation of a carcinoma of unknown origin. The results define the individual sensitivity of each marker and establish a baseline diagnostic profile of breast cancer in a large data set. In addition, the results support the use of immunohistochemical panel for confirming or determining breast as the source of metastasis.
27
Ahmedin Jemal, Rebecca L. Siegel, Jiaquan Xu et al. · CA A Cancer Journal for Clinicians · 2010 · 12.6K citations · Full text
Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2013 · 11.9K citations · Full text
GATA-3 Maintains the Differentiation of the Luminal Cell Fate in the Mammary Gland
Hosein Kouros‐Mehr, Euan M. Slorach, Mark D. Sternlicht et al. · Cell · 2006 · 692 citations · Full text
Markku Miettinen, Peter A. McCue, Maarit Sarlomo‐Rikala et al. · The American Journal of Surgical Pathology · 2013 · 683 citations · Full text
Dong-Hong Zhang, Lauren Cohn, Prabir Ray et al. · Journal of Biological Chemistry · 1997 · 664 citations · Full text